Last updated: 2026-09-09 05:49:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Immucell Corp. (ICCC) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $10.03, with a market capitalization of $89.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.52 to $12.10. This page covers its latest market performance, valuation, price trends and company information.
$89.91M | |
$9.82 | |
$25.55 | |
$1.33 | |
-- | |
15.29K | |
28.94K | |
-- | |
$12.10 | |
$4.52 | |
-- | |
-- |
Immucell Corp. (ICCC) last closed at $0.00 as of 2026-09-08 20:11:00, -- from the previous close of $0.00.
During the latest regular trading session, ICCC traded between $1.33 and $25.55, with a volume of 15.29K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Immucell Corp. (ICCC) moved from $10.02 to $10.03, representing a gain of 0.09% ($0.01).
The stock traded between $9.76 and $10.30 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 11.17 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 72.7%
ICCC is currently trading at $10.03, placing it 72.7% of the way from its 52-week low of $4.52 to its 52-week high of $12.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immucell Corp. (ICCC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.